Patients prefer telehealth for clinical trials, survey shows
Conducted with 136 US-based participants across multiple health conditions, the survey found that 63% said they would be more likely to join a trial if...
AI-driven Medable Studio speeds digital trial startups
Medable, a provider of clinical development technology, has announced a collaboration with Google Cloud to bring its decentralized clinical trial platform to Google Cloud Marketplace,...
Overcoming nonspecific binding challenges in PK assays
However, nonspecific binding (NSB) can hinder PK assays, impacting their accuracy and reliability. Fortunately, there are strategies and best practices to counter this issue. NSB...
Equity boost and partnership aim to accelerate GEMS platform’s efficiency
This forms part of an expanded partnership to enhance Genesis’ AI-powered drug discovery platform, GEMS (Genesis Exploration of Molecular Space). The new investment follows NVentures’...
Diabetes prevention – Eli Lilly’s Tirzepatide shows 23% weight loss
Eli Lilly has released detailed results from the SURMOUNT-1 phase 3 trial, where over 1,000 obese or overweight prediabetic participants were followed over the course...
AstraZeneca invests $3.5BN to boost US manufacturing power
With around $2 billion of the investment dedicated to creating more than a thousand U.S. jobs, AstraZeneca is looking to expand R&D and manufacturing facilities...
Decentralized clinical trials market expected to grow to $25BN
According to a recent report by Business Research Insights, the total size of the global decentralized clinical trials market was $7.14 billion in 2023, a...
Tech-driven solutions for patient access
While these sites are important for clinical research, they make patient recruitment challenging. Many participants are forced to travel to these locations for recurring visits,...
GHO and Ampersand acquire CDMO Avid Bioservices for $1.1 billion
Under the terms of the merger agreement, Avid Bioservices will be acquired by funds managed by GHO and Ampersand in a transaction valued at $1.1...
Merck, Abbisko’s oral drug aces phase 3 for rare tumors
According to the topline results, a total of 54% of patients given the treatment saw their tumors shrink compared to just 3.2% in the placebo...
Dexter Tjoa on Tjoapack’s journey and future in packaging
CEO Dexter Tjoa shares insights on the company’s journey, from early barcoding breakthroughs to embracing advanced technologies for patient safety, sustainability, and global compliance. Discover...
Axonis raises $115 million to treat epilepsy
Epilepsy is one of the most common neurological conditions in the world, with around 50 million people with the condition. There are a variety of...
Abzena unveils cell Line and ADC innovations at CPHI 2024
By offering comprehensive, integrated solutions, Abzena aims to streamline drug development processes and minimize risks for customers, helping to accelerate timelines and enhance production. OSP...
Middle School MD fosters youth interest in medical careers
The Palomar Health Foundation recently completed its third annual Middle School Medical Discoveries (Middle School MD) program, engaging local youth in immersive learning sessions aimed...
Novo Nordisk signs $285 million deal for a once-monthly Wegovy
Ascendis Pharma has granted Novo Nordisk an exclusive worldwide license to its TransCon technology platform for the development, manufacturing and commercialization of Novo’s products in...
Senhwa Biosciences starts trial of drug for rare cancers in children
Silmitasertib, also known as CX-4945, was originally developed by Cylene Pharmaceuticals, a San Diego-based biotech that ceased operations in 2013. Since then, Senhwa Biosciences, which...
Veeva’s Tim Davis on overcoming eCOA deployment challenges
Tim Davis, vice president of strategy at Veeva eCOA, had a conversation with Outsourcing Pharma’s senior editor, Liza Laws, and sheds light on how the...
MD Anderson investment supports groundbreaking cancer therapies
Starget Pharma, an Israeli startup developing AI-powered precision therapies for difficult-to-treat cancers, has secured a $5.1 million investment from MD Anderson Cancer Center’s Cancer Focus...
Novo Nordisk study – semaglutide reduces hospital admissions
Novo Nordisk has released data from the SELECT phase 3 trial showing that a 2.4 mg dose of semaglutide reduced the number of hospital admissions...
First-line leukemia therapy granted accelerated approval by FDA
Novartis’ Scemblix (asciminib) has received accelerated approval by the US FDA as a treatment for adult patients with newly diagnosed Philadelphia chromosome-positive myeloid leukemia in...